sameAs
Aspirin and the fibrinolytic responseThe role of endothelium in antithrombotic effect of the renin-angiotensin system blockade.Angiotensin-(1-7): an active member of the renin-angiotensin system.Short-term treatment with nitrate is not sufficient to induce in vivo antithrombotic effects in rats and mice.New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.Cannabinoids and haemostasis.Antithrombotic Potential of Tormentil Extract in Animal Models.Angiotensin-converting enzyme inhibitors attenuate propofol-induced pro-oxidative and antifibrinolytic effect in human endothelial cells.Quinapril decreases antifibrinolytic and prooxidative potential of propofol in arterial thrombosis in hypertensive rats.The acute prothrombotic effect of aldosterone in rats is partially mediated via angiotensin II receptor type 1.[Effect of Polfos on bleeding time. I. Changes in the formed elements of the blood in rats exposed to Polfos]The effect of tacrolimus (FK506) and cyclosporin A (CyA) on peripheral serotonergic mechanisms in uremic rats.[Prothrombotic aldosterone action--a new side of the hormone].[The influence of tissue and plasma angiotensin converting enzyme inhibitors on haemostasis with respect to experimental and clinical investigations].[Endothelial action of aldosterone--therapeutic implications from basic and clinical research]Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.Influence of acetaldehyde on the vasopressor effect of serotonin in pithed rats.Studies on the antithrombotic action of AT1 receptor antagonists.Effects of verapamil, diltiazem and nifedipine on some parameters of hemostasis in the rat.The involvement of AT(2)-receptor in the antithrombotic effect of losartan in renal hypertensive rats.The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan.Effects of Bulgarian red and white wines on primary hemostasis and experimental thrombosis in rats.Influence of ethanol and serotonin on rat platelet aggregation.The influence of propranolol on the hypotensive action of ketanserin in normotensive rats.Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency.Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.The serotonergic mechanisms are not involved in the inhibitory effect of captopril on rat platelet aggregation.Nitric oxide-dependent antiplatelet action of AT1-receptor antagonists in a pulmonary thromboembolism in mice.Antithrombotic effect of captopril and enalapril in young rats.Kynurenine metabolism in central nervous system in experimental chronic renal failure.Antithrombotic effect of captopril and enalapril in old rats.The effect of 'tissue' and 'plasma' angiotensin converting enzyme inhibitors on overall haemostatic potentials in rats.[Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer].A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.Hemodynamic effect of propofol in enalapril-treated hypertensive patients during induction of general anesthesia.Tissue distribution of a menthyl-conjugated oligodeoxyribonucleotide antisense to PAI-1 mRNA.Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats.A potent 5-hydroxytryptamine receptor (5-HT2A) antagonist, DV-7028, delays arterial thrombosis development in rats.Eplerenone reduces arterial thrombosis in diabetic rats.
P50
Q28165901-ACDDC8B2-868C-4773-BF85-85397232F932Q33819620-3BF8E917-512E-4B37-950C-BCD85E04CBEFQ35038914-0B82CB8E-6191-4019-AF7C-BCB044D229C9Q36164273-E01A06A6-38FB-495A-8AC7-DAC6364B187BQ37347190-F539C219-5802-44D2-8C4C-1D1C3057B6C1Q38358830-221A776C-5FBA-4A4D-8D01-4E47D4CF69A8Q38887820-0C392756-D329-4A19-AA58-32E79F5AA315Q41436535-82A7B85E-44BF-4428-8673-51339A172D02Q41936466-8A051226-A15F-4801-A580-2AD225D162C7Q41945916-3859C6E2-7034-442C-8325-507070C73E5BQ41949671-FA6840D9-71A1-47CC-8EAD-AD0D3DF21F8BQ42211824-207A57E6-3997-4565-98E9-FD8E472DED2DQ42553595-67FD3AB7-1924-45F6-9B2A-3CDD864FCFA4Q42850902-F6965152-47D8-4A64-ADBB-A8DF4F280297Q43043285-767D14E7-053E-440C-A9AA-1AF7DD9D8140Q43043287-A136B266-76AA-425E-9E1F-DF766E65ECB8Q43492610-85BC3668-92C9-422B-9BB7-5742B6184EECQ43537414-37818DDC-01DB-4140-9197-E3B13A5FC762Q43658703-BC0671FF-1920-47D9-8FF6-C3D23BC19D52Q43825788-8FBCD76C-ED0C-45E3-B678-F9D6E31D58BDQ43907226-41C12BFB-7EA0-4802-8A00-F6A12C17AB33Q43907228-DFD36AE0-8083-4172-94DA-F052169C21DAQ43929245-4DCDD522-85EF-4A9D-A97D-20B4CB6A73C8Q43978151-B91ADC3B-4F29-46AD-9922-47D95C4AAC7BQ44100209-C66AF2A5-C33C-413B-8A3C-17C7FDC3EE07Q44105651-D02DC9BB-FBBA-4685-9E61-7F2A3A63E21DQ44167942-1B10A1AC-4DBF-48A5-8D3C-074DF2FEEE0AQ44624116-5EC6A56F-5930-4537-B6C9-68EB2ADDFFF7Q44669352-99AE0C16-11A1-4CA7-8D43-F2F96EA4C591Q44817075-027DC041-BFAD-4B81-B031-734E4E6A7143Q44943849-8FA25045-52EB-4F1B-8AC4-7AF2217D10BDQ46453652-AF15BDFF-EBC1-4EE4-9BEA-C2B00A43116CQ46572544-ACEE999B-4B0C-4379-96DE-B5DFA285C2E2Q46671056-4ECD5E5F-005E-4C0B-B877-2F8254E75B99Q46692789-8C84FAA8-8F69-4B49-97FF-3BD57F7F4E18Q46755426-E9FDACEB-E0C3-4210-B6C7-417C7E150C94Q46815352-071FF1A4-AF55-4785-83AF-6B2BAB816EC9Q46878128-195CF1F5-AEF7-4D30-8474-EA1D573C392FQ47698631-318854B5-F803-4DD1-840A-55849FD27EF8Q51068066-0F458182-F5D2-4194-96A1-0B9932E15E84
P50
description
Polish pharmacologist
@en
Pools onderzoekster
@nl
cógaseolaí Polannach
@ga
polska farmakolog
@pl
name
Ewa Chabielska
@ast
Ewa Chabielska
@de
Ewa Chabielska
@en
Ewa Chabielska
@es
Ewa Chabielska
@fr
Ewa Chabielska
@ga
Ewa Chabielska
@it
Ewa Chabielska
@nl
Ewa Chabielska
@pl
Ewa Chabielska
@sl
type
label
Ewa Chabielska
@ast
Ewa Chabielska
@de
Ewa Chabielska
@en
Ewa Chabielska
@es
Ewa Chabielska
@fr
Ewa Chabielska
@ga
Ewa Chabielska
@it
Ewa Chabielska
@nl
Ewa Chabielska
@pl
Ewa Chabielska
@sl
altLabel
E Chabielska
@ast
E Chabielska
@en
E Chabielska
@nl
prefLabel
Ewa Chabielska
@ast
Ewa Chabielska
@de
Ewa Chabielska
@en
Ewa Chabielska
@es
Ewa Chabielska
@fr
Ewa Chabielska
@ga
Ewa Chabielska
@it
Ewa Chabielska
@nl
Ewa Chabielska
@pl
Ewa Chabielska
@sl
P214
P106
P1153
7003708149
P1559
Ewa Chabielska
@pl
P21
P213
0000 0001 1275 3948
P214
P27
P31
P3124
P496
0000-0002-8195-488X
P569
1959-01-01T00:00:00Z
P735
P7859
viaf-164418084